Zika and the Dengue Virus Vaccine
There is hope for the Zika virus but for now spraying is the first line of defense. Dengue is from the same family of flaviviruses as the Zika virus. Researchers indicated their findings may assist in the development of a vaccine against Zika which has been linked to surge in birth defects in Brazil (Durbin et al, 2016 ).
Our recommended mosquito spraying program includes:
Men in Black Mesquito Program
Every Three Weeks – For Three Months
We will treat the yard for mosquitoes every 3 weeks for 3 months for $195.
The program can be renewed for an additional 3 months at the same price.
The Center for Disease Control reports that as of February 2016, the Zika virus exists in Texas and reports over 300 cases nationwide and in many other states. The fifteen years of work on the Dengue vaccine has provided a much needed head start in the development of a Zika virus vaccine which continues to threaten Texas and most Gulf Coast states (C.D.C. Zika Virus, n.d.).
The Dengue virus is the world’s most common mosquito-borne virus. It infects some 390 million people each year in more than 120 countries of the world (Center for Disease Control, n.d.). More than two million people develop the Dengue with associated hemorrhagic fever which includes leaking blood vessels, severe headaches, pain behind the eyes, rash, pain in the joints, muscle or bone pain. It is the leaking blood vessels that make this virus so deadly with more than 25,000 deaths a year (C.D.C. Dengue, n.d.).
Anna Durbin, a researcher with the National Institutes of Health, announced a new vaccine has been introduced for Dengue, TV003. It has been tested in a group of 48 people – half of whom received the vaccine with the other half given a placebo (Hayden, 2016). The vaccine was created from a mixture of four weakened but live viruses, targeted to each of the four serotypes of Dengue. The vaccine, TV003, has been in development for 15 years with a history of demonstrated success in preventing Dengue 1, 3 and 4 viruses. Of the 41 people remaining in the study until its end, none showed evidence of Dengue (Durbin et al, 2016 ).
Durbin, A. P., Kirkpatrick, B. D., Pierce, K. K., Carmolli, M. P., Tibery, C. M., Grier, P. L., . . . Whitehead, S. S. (2016). A 12-Month–Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. Journal of Infectious Diseases J Infect Dis.
Center for Disease Control. (n.d.) Dengue. Retrieved March 31, 2016, from : http://www.cdc.gov/dengue/
Center for Disease Control. (n.d.) Zika Virus. Retrieved March 31, 2016, from http://www.cdc.gov/zika/
Center for Disease Control. (n.d.) Zika Virus in the United States. Retrieved March 31, 2016, from http://www.cdc.gov/zika/geo/united-states.html